您好,欢迎访问中国热带农业科学院 机构知识库!

Cancer cell membrane proteins-encapsulated nanovaccine enhances cancer immunotherapy and prevention by provoking antigen-specific cellular immunity via the dendritic cell-targeted delivery

文献类型: 外文期刊

作者: Luo, Xingyu 1 ; Chen, Xiaolu 2 ; Ma, Rongying 1 ; Fu, Zhaoming 1 ; Liu, Zuwei 1 ; Su, Qianhong 1 ; Fu, Huiling 1 ; Yang, Yong 1 ; Xue, Wei 3 ;

作者机构: 1.Hainan Univ, Sch Food Sci & Engn, Key Lab Food Nutr & Funct Food Hainan Prov, Haikou 570228, Peoples R China

2.Chinese Acad Trop Agr Sci, Trop Crops Genet Resources Inst, Haikou 570100, Peoples R China

3.Jinan Univ, Key Lab Biomat Guangdong Higher Educ Inst, Guangdong Prov Engn & Technol Res Ctr Drug Carrier, Dept Biomed Engn, Guangzhou 510632, Peoples R China

关键词: Metal-phenolic networks; Cancer nanovaccine; Mannose receptor; Cytotoxic T cell; Cancer immunotherapy

期刊名称:CHEMICAL ENGINEERING JOURNAL ( 影响因子:15.1; 五年影响因子:14.3 )

ISSN: 1385-8947

年卷期: 2024 年 481 卷

页码:

收录情况: SCI

摘要: Cancer nanovaccines offer a promising strategy for fighting against tumors, however, the engineering of cancer nanovaccines that can be easily fabricated with tanglesome cancer cell-derived antigens and elicit an adequately strong tumor-specific cellular immunity remains challenging. Herein, metal-phenolic networks (MPNs) are used as an antigen delivery platform to prepare the mannose-modified MPNs nanovaccine loaded with ovalbumin (OVA) and the immunoadjuvant CpG oligodeoxynucleotide (MMOC) through the facile self-assembly. When the model antigen OVA is substituted with cancer cell membrane proteins (CCMPs), the nanovaccine is called MMCC. MMOC markedly activates dendritic cells (DCs) via the mannose-mediated endocytosis and efficiently promotes the antigen cross-presentation, thus inspiring a robust antigen-specific CD8+ T cell response as well as immune memory effect in vivo. Consequently, MMOC exhibits admirable therapeutic and preventive results on E. G7-OVA tumors. Moreover, the combination use of MMCC with anti-PD1 significantly inhibits the growth of 4T1 tumors by strengthening the cellular immunity and decreasing the proportion of regulatory T cells (Tregs). The survival rate of 4T1 tumor-bearing mice in the prophylaxis assay is maintained at 100 % by MMCC over 42 days. Altogether, this study affords a universal and effective nanovaccine preparation strategy for cancer immunotherapy and prevention.

  • 相关文献
作者其他论文 更多>>